ArticleCellular immunology2019

In vivo administration of recombinant BTNL2-Fc fusion protein ameliorates graft-versus-host disease in mice.

Cheng Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.